Skip to main content
Premium Trial:

Request an Annual Quote

Startup Sera Prognostics Raises $1.4M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Women's health diagnostic test startup Sera Prognostics today said it has raised $1.4 million in a Series A-1 round, which will go toward development of a test for preterm birth risk.

Leading the A-1 round was UpStart Ventures, which founded Sera in 2008. Catalyst Health Ventures and individual investors also participated in the round. Dennis Farrar, a partner with UpStart, is the company's chairman and CEO.

The company is developing a blood-based test that measures proprietary biomarkers that it said is "highly" predictive of preterm birth risk. The biomarkers were identified by Steven Graves, a professor of chemistry and biochemistry at Brigham Young University, and M. Sean Esplin, an associate professor and high-risk obstetrician at the University of Utah School of Medicine and co-founder of Sera Prognostics, the firm said.

The Salt Lake City-based firm has licensed the serum proteomics discovery technology and novel peptides, which are detectable only in pregnant women. Using the biomarkers, Sera was able to detect in two studies with greater than 90 percent accuracy women who went on to have preterm birth, when tested at 24 and 28 weeks of gestation, it said in a statement.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.